Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for ...

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

21, 2025 -- The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed. The drug ...

the new drug, called an aromatase inhibitor, shuts down the body's oestrogen supply altogether. Arimidex is currently licensed for treatment of early breast cancer only in Japan, but manufacturers ...

Compared with endocrine therapy, radiotherapy was associated with a smaller reduction in health-related quality-of-life in ...

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression. Houston Methodist and ...

Despite significant therapeutic advances, breast ... drugs are better tolerated than chemotherapy, they still have side effects that diminish quality of life and can leave people at risk for ...

With the RSK1 inhibitor already in clinical testing, the path to expanded use as a treatment for blood ... subjects with metastatic breast cancer have tolerated the drug well with low-grade ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated ...

A new study has found a way to treat patients with triple-negative breast cancer using a shorter and less toxic treatment plan while achieving similar results to the current standard. The study, ...

The German company’s drug met all the goals of a late-stage study for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes, caused by breast-cancer treatments.